Basic Profile
 
If you'd like to claim this profile on behalf of your company, please Contact Us.
 

Latest news ...

Some of our recent news articles.

 
16
November
2020
16th November 2020
 

Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m

Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.


The three-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150m across redevelopment, equipment and personnel.


The CDMO which specializes in the production of oncolytic viruses, viral vector vaccines and viral vector gene therapy products, expects the site to be operational by the second half of 2021.


 



 



Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.


The three-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150m across redevelopment, equipment and personnel.


The CDMO which specializes in the production of oncolytic viruses, viral vector vaccines and viral vector gene therapy products, expects the site to be operational by the second half of 2021.


The facility will be equipped with state-of the-art technology and enable a significant capacity increase, including 2000L scale bioreactors and additional fill-finish capabilities.


Vibalogics’ Chief Executive Officer Tom Hochuli is leading the CDMO’s U.S. expansion and global growth strategy. He said: “We are very excited about our choice of facility, as it meets both our current and future needs, giving us the ability to expand further to meet growing customer demand.



 
Read the full story »
 
 
16
November
2020
16th November 2020
 

Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m

Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.


The three-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150m across redevelopment, equipment and personnel.


The CDMO which specializes in the production of oncolytic viruses, viral vector vaccines and viral vector gene therapy products, expects the site to be operational by the second half of 2021.SCROLL DOWN


 



Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.


The three-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150m across redevelopment, equipment and personnel.


The CDMO which specializes in the production of oncolytic viruses, viral vector vaccines and viral vector gene therapy products, expects the site to be operational by the second half of 2021.


The facility will be equipped with state-of the-art technology and enable a significant capacity increase, including 2000L scale bioreactors and additional fill-finish capabilities.


Vibalogics’ Chief Executive Officer Tom Hochuli is leading the CDMO’s U.S. expansion and global growth strategy. He said: “We are very excited about our choice of facility, as it meets both our current and future needs, giving us the ability to expand further to meet growing customer demand.



 
Read the full story »
 
 
16
November
2020
16th November 2020
 

Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m

Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.


The three-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150m across redevelopment, equipment and personnel.


The CDMO which specializes in the production of oncolytic viruses, viral vector vaccines and viral vector gene therapy products, expects the site to be operational by the second half of 2021.

 
Read the full story »
 
 
16
November
2020
16th November 2020
 

Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m

Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.


The three-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150m across redevelopment, equipment and personnel.


The CDMO which specializes inruses, viral vector vaccines and viral vector gene therapy products, expects the site to be operational by the second half of 2021. the production of oncolytic vi

 
Read the full story »
 
 
16
November
2020
16th November 2020
 

Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m

Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.


The three-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150m across redevelopment, equipment and personnel.


The CDMO which specializes inruses, viral vector vaccines and viral vector gene therapy products, expects the site to be operational by the second half of 2021. the production of oncolytic vi

 
Read the full story »
 
 
16
November
2020
16th November 2020
 

Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m

Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.


The three-year investment plan includes the build out of a 110,000 sq. ft facility totalling $150m across redevelopment, equipment and personnel.


 

 
Read the full story »
 
 
16
November
2020
16th November 2020
 

Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m

With the race for COVID-19 vaccines heating up and the cell and gene therapy market booming, contract manufacturers in the viral vector space are quickly bulking up to meet demand. Hoping to ride that wave, Germany's Vibalogics is planting its flag in the U.S. with a new leader in place. 


 

Months after appointing a new global CEO, German contract manufacturer Vibalogics will shell out $150 million to build out a 110,000-square-foot "virotherapy" facility near Boston set to come online in the second half of 2021, the company said Wednesday. 


The new facility will be built out over three years and eventually house 2,000 liters of bioreactor capacity, dedicated to producing clinical and commercial-stage oncolytic viruses and viral vectors used in vaccines and cell and gene therapies, Vibalogics said in a release. The work may include manufacturing for Johnson & Johnson's COVID-19 vaccine candidate under a deal the partners inked in May.

 
Read the full story »
 
 
16
November
2020
16th November 2020
 

Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m

Vibalogics establishes U.S. presence with virotherapy facility in Boston and plans to invest $150m

 
Read the full story »
 
 
 
 
 
 
 
 
 

About Us

SURIMS is the new name for Actex Pharma Services which was a consultancy established in 2003, supporting companies in the identification, qualification and management of quality vendors and suppliers in ingredients and formulations.

The Pharmaceutical Services Directory supports the identification and on-boarding of quality suppliers and also incorporates software features that manage relationships between suppliers and their customers. These include the building and deployment of questionnaires and assessments, electronic signatures and sign-offs and project management between vendor/partner and customer.

Access to the features and software is available on a 'pay as you go' basis, or a customised version can be licensed for your company for its own supplier on-boarding and supplier management activities. Further information on our software services please contact Tel: +353 87 294 0436 or email info@surims.com

 
 
 

Get in Touch

The Pharmaceutical Services Directory
info@surims.com

 
 
 

© 2020 Surims Ltd | All Rights Reserved.